Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells

Joong Sup Shim, Jiyong Lee, Kyung Noo Kim, Ho Jeong Kwon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.

Original languageEnglish
Pages (from-to)747-751
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume359
Issue number3
DOIs
Publication statusPublished - 2007 Aug 3

Fingerprint

Calmodulin
Colorectal Neoplasms
Cells
G1 Phase Cell Cycle Checkpoints
Phosphorylation
Drug Design
Therapeutic Uses
Colonic Neoplasms
Cell Cycle
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

@article{5240d553b7854ca9968f4d2be28797b1,
title = "Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells",
abstract = "We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.",
author = "Shim, {Joong Sup} and Jiyong Lee and Kim, {Kyung Noo} and Kwon, {Ho Jeong}",
year = "2007",
month = "8",
day = "3",
doi = "10.1016/j.bbrc.2007.05.174",
language = "English",
volume = "359",
pages = "747--751",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. / Shim, Joong Sup; Lee, Jiyong; Kim, Kyung Noo; Kwon, Ho Jeong.

In: Biochemical and Biophysical Research Communications, Vol. 359, No. 3, 03.08.2007, p. 747-751.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells

AU - Shim, Joong Sup

AU - Lee, Jiyong

AU - Kim, Kyung Noo

AU - Kwon, Ho Jeong

PY - 2007/8/3

Y1 - 2007/8/3

N2 - We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.

AB - We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.

UR - http://www.scopus.com/inward/record.url?scp=34250208088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250208088&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2007.05.174

DO - 10.1016/j.bbrc.2007.05.174

M3 - Article

VL - 359

SP - 747

EP - 751

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -